Biotech startup Kite Pharma has raised $35m for cancer-fighting technologies in a series A round backed by a syndicate of investors. The Los Angeles-based startup announced that it has closed $20m in new funds, as well as converting $15m in outstanding promissory notes into series A preferred stock. Life science VC Alta Partners, VC firm…
Kite flies with $35m
Jun 7, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024